Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Nana Brochmann, Esben Meulengracht Flachs, Anne Illemann Christensen, Christen Lykkegaard Andersen, Knud Juel, Hans Carl Hasselbalch & Ann-Dorthe Zwisler. (2017) A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents. Clinical Epidemiology 9, pages 141-150.
Read now
Read now
Silvan Francke, Anna Mies, Manja Meggendorfer, Uta Oelschlaegel, Ekaterina Balaian, Silke Gloaguen, Torsten Haferlach, Gerhard Ehninger, Martin Bornhäuser & Uwe Platzbecker. (2017) Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2. Leukemia & Lymphoma 58:5, pages 1271-1272.
Read now
Read now
Articles from other publishers (19)
Lai Yee Orbell, Nouf Abutheraa, Andrew S Duncombe, Mary Frances McMullin, Ruben Mesa, Charlene M McShane, Glen James & Lesley A Anderson. (2023)
The
JAK2
V617F
mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
. eJHaem 4:4, pages 1071-1080.
Crossref
Crossref
Jeanne Palmer & Ruben Mesa. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
13
.
Heidi E. Kosiorek, Robyn M. Scherber, Holly L. Geyer, Srdan Verstovsek, Blake T. Langlais, Gina L. Mazza, Jason Gotlib, Vikas Gupta, Leslie J. Padrnos, Jeanne M. Palmer, Angela Fleischman, Ruben A. Mesa & Amylou C. Dueck. (2022)
Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment
(COMFORT)‐I
study
. British Journal of Haematology 198:6, pages 1065-1068.
Crossref
Crossref
Krisstina Gowin, Blake T. Langlais, Heidi E. Kosiorek, Amylou Dueck, Denise Millstine, Jennifer Huberty, Ryan Eckert & Ruben A. Mesa. (2020) The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms. Cancer Medicine 9:24, pages 9445-9453.
Crossref
Crossref
Nana Brochmann, Esben Meulengracht Flachs, Anne Illemann Christensen, Marie Bak, Christen Lykkegaard Andersen, Knud Juel & Ann-Dorthe Zwisler. (2020) Health-Related Quality of Life in Patients with Philadelphia-Negative Myeloproliferative Neoplasms: A Nationwide Population-Based Survey in Denmark. Cancers 12:12, pages 3565.
Crossref
Crossref
Jeanne Palmer & Ruben Mesa. (2020) The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis. Therapeutic Advances in Hematology 11, pages 204062072092520.
Crossref
Crossref
Jeanne Palmer, Heidi E. Kosiorek, Christine Wolschke, Veena D.S. Fauble, Richard ButterfieldIIIIII, Holly Geyer, Robyn M. Scherber, Amylou C. Dueck, Allison Gathany, Ruben A. Mesa & Nicolaus Kroger. (2019) Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis. Biology of Blood and Marrow Transplantation 25:11, pages 2267-2273.
Crossref
Crossref
Lucia Masarova, Prithviraj Bose & Srdan Verstovsek. (2019) The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports 14:4, pages 310-327.
Crossref
Crossref
Prathibha Surapaneni & Robyn M. Scherber. (2019) Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions. Current Hematologic Malignancy Reports 14:3, pages 164-170.
Crossref
Crossref
Jennifer Huberty, Ryan Eckert, Linda Larkey, Krisstina Gowin, Jules Mitchell & Ruben Mesa. (2018) Perceptions of Myeloproliferative Neoplasm Patients Participating in an Online Yoga Intervention: A Qualitative Study. Integrative Cancer Therapies 17:4, pages 1150-1162.
Crossref
Crossref
Kasper Mønsted Pedersen, Graziella Zangger, Nana Brochmann, Birk Mygind Grønfeldt, Ann-Dorthe Zwisler, Hans Carl Hasselbalch & Lars Hermann Tang. (2018) The effectiveness of exercise-based rehabilitation to patients with myeloproliferative neoplasms-An explorative study. European Journal of Cancer Care 27:5, pages e12865.
Crossref
Crossref
Arief Gunawan, Patrick Harrington, Natalia Garcia-Curto, Donal McLornan, Deepti Radia & Claire Harrison. (2018) Ruxolitinib for the Treatment of Essential Thrombocythemia. HemaSphere 2:4, pages e56.
Crossref
Crossref
Ryan Eckert, Jennifer Huberty, Krisstina Gowin, Ruben Mesa & Lisa Marks. (2016) Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research. Integrative Cancer Therapies 16:4, pages 439-450.
Crossref
Crossref
Jeanne Palmer & Ruben Mesa. (2017) Transplantation in Myelofibrosis Reaches the Molecular Age. Biology of Blood and Marrow Transplantation 23:7, pages 1043-1044.
Crossref
Crossref
晓婧 李. (2017) The Symptom Management of Myeloproliferative Neoplasms. Advances in Clinical Medicine 07:02, pages 59-65.
Crossref
Crossref
Daniel V. Levy, Joseph A. Sclafani & Roger P. Bakale. (2016) An Improved Synthesis of the Free Base and Diglycolate Salt of CEP-33779; A Janus Kinase 2 Inhibitor. Organic Process Research & Development 20:12, pages 2085-2091.
Crossref
Crossref
C. Zeidler, B. Pfleiderer & S. Ständer. (2016) Neues zur Therapie des chronischen PruritusNew treatment options for chronic pruritus. Der Hautarzt 67:8, pages 627-634.
Crossref
Crossref
Brianna E. Vaa, Ayalew Tefferi, Naseema Gangat, Animesh Pardanani, Terra L. Lasho, Christy M. Finke & Alexandra P. Wolanskyj. (2016) Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. Annals of Hematology 95:7, pages 1185-1189.
Crossref
Crossref
Naveen Pemmaraju, Vikas Gupta, Ruben Mesa & Michael A. Thompson. (2015) Social Media and Myeloproliferative Neoplasms (MPN)—Focus on Twitter and the Development of a Disease-specific Community: #MPNSM. Current Hematologic Malignancy Reports 10:4, pages 413-420.
Crossref
Crossref